S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in

Flexion Therapeutics Stock Forecast, Price & News

+0.12 (+1.05 %)
(As of 01/22/2021 12:00 AM ET)
Today's Range
Now: $11.54
50-Day Range
MA: $11.83
52-Week Range
Now: $11.54
Volume961,453 shs
Average Volume611,396 shs
Market Capitalization$569.10 million
P/E RatioN/A
Dividend YieldN/A
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201, a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, an administered NaV1.7 inhibitor for the management of post-operative pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.
Flexion Therapeutics logo


Overall MarketRank

1.43 out of 5 stars

Medical Sector

517th out of 1,923 stocks

Pharmaceutical Preparations Industry

258th out of 773 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:FLXN



Sales & Book Value

Annual Sales$72.96 million
Book Value($0.53) per share


Net Income$-149,770,000.00
Net Margins-153.90%


Market Cap$569.10 million
Next Earnings Date3/11/2021 (Estimated)
+0.12 (+1.05 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FLXN News and Ratings via Email

Sign-up to receive the latest news and ratings for FLXN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Flexion Therapeutics (NASDAQ:FLXN) Frequently Asked Questions

How has Flexion Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Flexion Therapeutics' stock was trading at $12.31 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, FLXN stock has decreased by 6.3% and is now trading at $11.54.
View which stocks have been most impacted by COVID-19

Is Flexion Therapeutics a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last twelve months. There are currently 1 hold rating, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Flexion Therapeutics stock.
View analyst ratings for Flexion Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Flexion Therapeutics?

Wall Street analysts have given Flexion Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Flexion Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Flexion Therapeutics' CEO?

1,448 employees have rated Flexion Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Flexion Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Flexion Therapeutics' next earnings date?

Flexion Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Flexion Therapeutics

How were Flexion Therapeutics' earnings last quarter?

Flexion Therapeutics, Inc. (NASDAQ:FLXN) posted its quarterly earnings results on Wednesday, November, 4th. The specialty pharmaceutical company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by $0.01. The specialty pharmaceutical company had revenue of $23.66 million for the quarter, compared to the consensus estimate of $23.59 million.
View Flexion Therapeutics' earnings history

What guidance has Flexion Therapeutics issued on next quarter's earnings?

Flexion Therapeutics issued an update on its FY 2020 Pre-Market earnings guidance on Wednesday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $85.5-85.5 million, compared to the consensus revenue estimate of $84.88 million.

What price target have analysts set for FLXN?

11 equities research analysts have issued 1 year price targets for Flexion Therapeutics' shares. Their forecasts range from $15.00 to $35.00. On average, they expect Flexion Therapeutics' stock price to reach $20.73 in the next twelve months. This suggests a possible upside of 79.6% from the stock's current price.
View analysts' price targets for Flexion Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Flexion Therapeutics' key competitors?

What other stocks do shareholders of Flexion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Cara Therapeutics (CARA), Aduro Biotech (ADRO), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX) and Verastem (VSTM).

Who are Flexion Therapeutics' key executives?

Flexion Therapeutics' management team includes the following people:
  • Dr. Michael D. Clayman, Co-Founder, Pres, CEO & Director (Age 68, Pay $1.06M)
  • Dr. Neil Bodick, Consultant (Age 73, Pay $657.6k)
  • Dr. Scott D. Kelley, Chief Medical Officer (Age 61, Pay $626.53k)
  • Mr. David A. Arkowitz M.B.A., Chief Financial Officer (Age 59)
  • Scott Young, VP of Corp. Communications & Investor Relations
  • Ms. Carolyn Beaty Scimemi, VP, Legal Affairs & Chief Compliance Officer
  • Mr. Mark S. Levine, Gen. Counsel & Corp. Sec. (Age 47)
  • Mr. John Magee, VP of Sales
  • Ms. Christina Willwerth, Chief Strategy Officer (Age 49)
  • Ms. Kerry A. Wentworth, Chief Regulatory Officer (Age 47)

What is Flexion Therapeutics' stock symbol?

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

Who are Flexion Therapeutics' major shareholders?

Flexion Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.97%). Company insiders that own Flexion Therapeutics stock include Adam Muzikant, C Ann Merrifield, David Arkowitz, Mark S Levine, Mark Stejbach, Michael D Clayman and Samuel D Colella.
View institutional ownership trends for Flexion Therapeutics

Which major investors are selling Flexion Therapeutics stock?

FLXN stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. Company insiders that have sold Flexion Therapeutics company stock in the last year include Adam Muzikant, David Arkowitz, and Mark S Levine.
View insider buying and selling activity for Flexion Therapeutics
or view top insider-selling stocks.

How do I buy shares of Flexion Therapeutics?

Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Flexion Therapeutics' stock price today?

One share of FLXN stock can currently be purchased for approximately $11.54.

How big of a company is Flexion Therapeutics?

Flexion Therapeutics has a market capitalization of $569.10 million and generates $72.96 million in revenue each year. The specialty pharmaceutical company earns $-149,770,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis. Flexion Therapeutics employs 288 workers across the globe.

What is Flexion Therapeutics' official website?

The official website for Flexion Therapeutics is www.flexiontherapeutics.com.

How can I contact Flexion Therapeutics?

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]

This page was last updated on 1/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.